GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK plc announced the acquisition of ordinary shares by several key executives under the ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million. Meanwhile, the EPS declined to EGP 0.85 from EGP 1.19. In April-June 2025, ...

A month has gone by since the last earnings report for GSK (GSK). Shares have added about 3.2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up ...

GlaxoSmithKline (GSK) closed at $45.06 in the latest trading session, marking a -0.4% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.42%. At the same time ...

GlaxoSmithKline has picked a familiar face to lead its consumer health business after a planned spinoff next year. Hint: It’s not group CEO Emma Walmsley. Brian McNamara, currently head of GSK ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.

GlaxoSmithKline (LSE:GSK), is undergoing a transformation and the company is expected to split into 2 entities mid 2022. Shareholders had an underwhelming performance in the last 3 years, and the ...

The deal includes a $90 million upfront payment from GSK. GlaxoSmithKline entered into a $180 million collaboration deal with German biopharmaceutical company CureVac to jointly develop a next ...